Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 4/20 | 0.44 |
| ▸ | ACE | P12821 | 4/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.43 |
| ▸ | CPA1 | P15085 | 3/20 | 0.42 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297974 | 1.00 | PTPN1 (0.47) | PTPN1SCN9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3993344 | 1.00 | PTPN1 (0.47) | PTPN1SCN9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3991130 | 0.97 | PTPN1 (0.47) | PTPN1SCN9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3998651 | 0.97 | PTPN1 (0.47) | PTPN1SCN9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3993121 | 0.94 | SCN9A (0.48) | PTPN1SCN9AMMEACEACE2 | |
| SCHEMBL3993383 | 0.94 | PTPN1 (0.48) | PTPN1SCN9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3989620 | 0.93 | MEN1 (0.55) | PTPN1SCN9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3992786 | 0.93 | MEN1 (0.55) | PTPN1SCN9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3991728 | 0.93 | KMT2A (0.50) | PTPN1SCN9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3993869 | 0.93 | GPR132 (0.45) | PTPN1SCN9AKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1660439-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | PTPN1 1846/4885SCN9A 1200/4885KMT2A 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.